Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Enterovirus 71 vaccine provides protection against EV71-associated hand, foot, and mouth disease

A publication in this week's issue of the New England Journal of Medicine evaluates the efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China.

News image

Enterovirus 71 (EV71) is one of the major causative agents of outbreaks of hand, foot, and mouth disease or herpangina worldwide.

This phase 3 trial was designed to evaluate the efficacy, safety, and immunogenicity of an EV71 vaccine.

Dr Fengcai Zhu and colleagues from China conducted a randomized, double-blind, placebo-controlled, multicenter trial in which 10,007 healthy infants and young children were randomly assigned in a 1:1 ratio to receive 2 intramuscular doses of either EV71 vaccine or placebo, 28 days apart.

The surveillance period was 12 months.

The team's primary end point was the occurrence of EV71-associated hand, foot, and mouth disease or herpangina.

Vaccine efficacies against EV71-associated hospitalization was 100%
New England Journal of Medicine

During the 12-month surveillance period, EV71-associated disease was identified in 0.3% of vaccine recipients, and 2.1% of placebo recipients in the intention-to-treat cohort.

The team found that this vaccine efficacy against EV71-associated hand, foot, and mouth disease or herpangina was 95% in this cohort.

Vaccine efficacies against EV71-associated hospitalization and hand, foot, and mouth disease with neurologic complications were both 100%.

The team observed that serious adverse events occurred in about 2% of children in the vaccine group, and about 3% of children in the placebo group.

In the immunogenicity subgroup, an anti-EV71 immune response was elicited by the 2-dose vaccine series in 99% of participants at day 56.

The researchers observed that an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71-associated hand, foot, and mouth disease or herpangina.

Dr Zhu and team comment, "The EV71 vaccine provided protection against EV71-associated hand, foot, and mouth disease or herpangina in infants and young children. "

N Engl J Med 2014; 370:818-828
28 February 2014

Go to top of page Email this page Email this page to a colleague

 04 May 2015

Advanced search
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Response to sorafenib in hepatocellular carcinoma
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Clinical outcomes after esophagectomy
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity
 22 April 2015 
Hepatitis and mortality in hospitalized patients
 22 April 2015 
Magnetic sphincter augmentation for GERD
 22 April 2015 
Drug, herbal and dietary supplement hepatotoxicity
 21 April 2015 
Risk factors of postpartum bowel changes
 21 April 2015 
Tracking colonoscopy surveillance intervals
 21 April 2015 
PPI increases risk of cryptogenic liver abscess
 20 April 2015 
IBS after traveller's diarhea
 20 April 2015 
Adherence to Hep C treatments
 20 April 2015 
Economic impact of C. diff infection
 17 April 2015 
Synchronous colorectal advanced neoplasia
 17 April 2015 
PNPLA3 polymorphisms and NAFLD risk
 17 April 2015 
MELD score and colorectal resection
 16 April 2015 
Bleeding risk in colonic diverticulosis
 16 April 2015 
Minority use of high-volume hospitals for colorectal cancer
 16 April 2015 
Sleep and IBD
 15 April 2015 
Treatment of hepatocellular carcinoma
 15 April 2015 
Score predicts malignant bile duct obstruction
 15 April 2015 
Increased risk of Barrett esophagus
 14 April 2015 
Improving colorectal cancer screening uptake
 14 April 2015 
Colorectal cancer presenting under the age of 50
 14 April 2015 
Functional constipation vs constipation predominant IBS
 13 April 2015 
Fecal transplant for C. difficile
 13 April 2015 
Immune based treatments for HCC
 13 April 2015 
CRP and acute diverticulitis
 10 April 2015 
Adjuvant therapy after rectal cancer
 10 April 2015 
Viral outcomes in HCV infection
 10 April 2015 
Hypnotherapy for IBS
 09 April 2015 
Male IBD patients wishing to conceive
 09 April 2015 
Screening programs based on the fecal immunochemical test
 09 April 2015 
Management of esophageal food impaction
 08 April 2015 
Ambulatory hemorrhoidal surgery
 08 April 2015 
Iron fortification and gut inflammation
 08 April 2015 
Nonceliac gluten sensitivity
 07 April 2015 
Treatment of Hep C virus
 07 April 2015 
Interventions for eosinophilic esophagitis
 07 April 2015 
Endoscopic managements of GI bleeds
 06 April 2015 
Risk stratifying Barrett's esophagus
 06 April 2015 
Cost-effectiveness of HCV
 06 April 2015 
Treatment for rectal cancer
 03 April 2015 
Vitamin D deficiency and Hep B outcomes
 03 April 2015 
Hepatocellular carcinoma surveillance in cirrhosis
 03 April 2015 
Predicting advanced cancer in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us